Innoviva (INVA) Gross Profit (2011 - 2026)
Innoviva's (INVA) quarterly Gross Profit came in at $75.8 million in Q1 2026, up 3.43% YoY from $73.3 million in Q1 2025, and down 67.31% on a QoQ basis from $232.0 million in Q3 2025.
Analysis
Innoviva (INVA) Gross Profit (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 9 years of Gross Profit data on file, last reported at $75.8 million in Q1 2026.
- Quarterly Gross Profit rose 3.43% year-over-year to $75.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $464.3 million (up 6.37% YoY) and the FY2025 annual result came in at $307.7 million, up 3.87% from the prior year.
- Gross Profit declined to $75.8 million in Q1 2026, from $232.0 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $261.9 million in Q3 2022 to a low of -$6.2 million in Q2 2023.
- A 5-year average of $101.0 million and a median of $75.8 million in 2026 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2023 — Gross Profit slumped 249.76% — and 2024, when it surged 24227.13%.
- Tracing INVA's Gross Profit over 5 years: stood at $261.9 million in 2022, then declined by 14.83% to $223.0 million in 2023, then dropped by 2.22% to $218.1 million in 2024, then rose by 6.38% to $232.0 million in 2025, then sank by 67.31% to $75.8 million in 2026.
- The last three Gross Profit figures came in at $75.8 million (Q1 2026), $232.0 million (Q3 2025), and $83.1 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 90.62 Mn |
| Mar 31, 2026 | 75.83 Mn |
| Sep 30, 2025 | 232.00 Mn |
| Jun 30, 2025 | 83.15 Mn |
| Mar 31, 2025 | 73.32 Mn |
| Sep 30, 2024 | 218.08 Mn |
| Jun 30, 2024 | 84.99 Mn |
| Mar 31, 2024 | 60.09 Mn |
| Sep 30, 2023 | 196.71 Mn |
| Jun 30, 2023 | 72.01 Mn |
| Mar 31, 2023 | 67.62 Mn |
| Sep 30, 2022 | 261.86 Mn |
| Jun 30, 2022 | 108.22 Mn |
| Mar 31, 2022 | 90.06 Mn |
| Sep 30, 2021 | 284.19 Mn |
| Mar 31, 2014 | 592,000.00 |
| Mar 31, 2013 | 1.32 Mn |
| Dec 31, 2011 | 5.36 Mn |
| Sep 30, 2011 | 6.43 Mn |
| Jun 30, 2011 | 5.21 Mn |